GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Equillium Inc (STU:0FY) » Definitions » Dividend-Payout-to-FFO

Equillium (STU:0FY) Dividend-Payout-to-FFO


View and export this data going back to 2020. Start your Free Trial

What is Equillium Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.


Equillium (STU:0FY) Business Description

Traded in Other Exchanges
Address
2223 Avenida De La Playa, Suite 105, La Jolla, CA, USA, 92037
Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.